288 related articles for article (PubMed ID: 19362990)
1. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.
Berentsen S
Clin Lymphoma Myeloma; 2009 Mar; 9(1):110-2. PubMed ID: 19362990
[TBL] [Abstract][Full Text] [Related]
2. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
3. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins).
Crisp D; Pruzanski W
Am J Med; 1982 Jun; 72(6):915-22. PubMed ID: 6807086
[TBL] [Abstract][Full Text] [Related]
4. [A case of Waldenström's macroglobulinemia with cold agglutinin disease].
Suzuki M; Noda T; Kodama H; Sahashi K; Wakita A
Rinsho Ketsueki; 1986 Mar; 27(3):376-80. PubMed ID: 3090303
[No Abstract] [Full Text] [Related]
5. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Tanaka H; Hashimoto S; Sugita Y; Sakai S; Takeda Y; Abe D; Takagi T; Nakaseko C
Int J Hematol; 2012 Oct; 96(4):501-5. PubMed ID: 22878940
[TBL] [Abstract][Full Text] [Related]
6. Improvement of the thermal amplitude after rituximab treatment for cold agglutinin disease with Waldenström's macroglobulinemia.
Hattori N; Ishii N; Ariizumi H; Adachi D; Matsuda I; Nakamaki T; Tomoyasu S
Ann Hematol; 2010 Jan; 89(1):103-4. PubMed ID: 19513714
[No Abstract] [Full Text] [Related]
7. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom's macroglobulinemia.
Stone MJ
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):157-9. PubMed ID: 21454221
[TBL] [Abstract][Full Text] [Related]
9. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
10. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenström's macroglobulinemia.
Aslan DL; Peterson BA; Long-Tsai M; Eastlund T
Transfusion; 2006 Jan; 46(1):90-4. PubMed ID: 16398735
[TBL] [Abstract][Full Text] [Related]
11. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.
Berentsen S; Beiske K; Tjønnfjord GE
Hematology; 2007 Oct; 12(5):361-70. PubMed ID: 17891600
[TBL] [Abstract][Full Text] [Related]
12. B-lymphocytes as targets for therapy in chronic cold agglutinin disease.
Berentsen S; Ulvestad E; Tjønnfjord GE
Cardiovasc Hematol Disord Drug Targets; 2007 Sep; 7(3):219-27. PubMed ID: 17896962
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.
Berentsen S; Tjønnfjord GE
Blood Rev; 2012 May; 26(3):107-15. PubMed ID: 22330255
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody activity in Waldenstrom's macroglobulinemia.
Stone MJ; Merlini G; Pascual V
Clin Lymphoma; 2005 Mar; 5(4):225-9. PubMed ID: 15794853
[TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
Merchionne F; Procaccio P; Dammacco F
Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
[TBL] [Abstract][Full Text] [Related]
17. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
18. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune hemolytic anemia with warm antibodies complicated with an intercurrent attack of hemolysis with cold agglutinins in a case of Waldenström disease.
Gologan R; Dima I; Butoianu E; Nicoară S; Coliţă D
Rom J Intern Med; 1996; 34(1-2):149-54. PubMed ID: 8908641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
